gabapentin has been researched along with Clasp-Knife Spasticity in 19 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 9.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 9.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Behavioural assessments of tail muscle spasticity and mean arterial blood pressure responses to noxious somatic and/or visceral stimulation were used to test the effects of GBP on these abnormal reflexes." | 5.37 | Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. ( Duale, H; Kitzman, PH; Lyttle, TS; O'Dell, CR; Patel, SP; Rabchevsky, AG, 2011) |
| "To investigate the effect of gabapentin on subject self-report and physician-administered spasticity scales in individuals with multiple sclerosis." | 5.09 | Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. ( Cutter, NC; Johnson, JC; Scott, DD; Whiteneck, G, 2000) |
| "At a dose of 400mg orally three times a day, gabapentin may be of value in the treatment of the spasticity and painful muscle cramping experienced by patients with multiple sclerosis." | 5.08 | Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997) |
| "Gabapentin or placebo was given orally in doses 400 mg three times daily for 48 h." | 2.68 | Effectiveness of gabapentin in controlling spasticity: a quantitative study. ( Graves, DE; Mueller, M; Olson, WH; Priebe, MM; Sherwood, AM, 1997) |
| "As some patients with spasticity are either refractory to or intolerant of established medical treatments, we conducted this study to investigate the effect of gabapentin on spasticity in patients with spinal cord injury." | 2.68 | Gabapentin for the treatment of spasticity in patients with spinal cord injury. ( Gruenthal, M; Mueller, M; Olson, WH; Olson, WL; Priebe, MM; Sherwood, AM, 1997) |
| "Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| "Gabapentin is a novelty, and the working mechanism of cannabis has been elucidated." | 2.46 | Spasticity: revisiting the role and the individual value of several pharmacological treatments. ( Kuks, JB; Lapeyre, E; Meijler, WJ, 2010) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Treatment of spasticity includes oral and intrathecal anti-spastic drugs, muscle injections with relaxant agents, physical therapy, electrical and magnetic stimulation and peripheral nerve stimulation, alone or in various combinations." | 1.56 | Italian consensus on treatment of spasticity in multiple sclerosis. ( Centonze, D; Comi, G; Leocani, L; Otero-Romero, S; Solari, A, 2020) |
| "Behavioural assessments of tail muscle spasticity and mean arterial blood pressure responses to noxious somatic and/or visceral stimulation were used to test the effects of GBP on these abnormal reflexes." | 1.37 | Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. ( Duale, H; Kitzman, PH; Lyttle, TS; O'Dell, CR; Patel, SP; Rabchevsky, AG, 2011) |
| "Both spastic behavior and electromyography (EMG) activity were significantly decreased at 1 and 3 h post-GBP injection when compared with the activity level following administration of saline." | 1.34 | Gabapentin suppresses spasticity in the spinal cord-injured rat. ( Dwyer, MK; Kitzman, PH; Uhl, TL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Comi, G | 2 |
| Solari, A | 1 |
| Leocani, L | 1 |
| Centonze, D | 1 |
| Otero-Romero, S | 2 |
| Kopacz, A | 1 |
| Ludwig, C | 1 |
| Tarbox, M | 1 |
| Trojano, M | 1 |
| Sastre-Garriga, J | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Thompson, AJ | 1 |
| Vermersch, P | 1 |
| Gold, R | 1 |
| Montalban, X | 1 |
| Rabchevsky, AG | 1 |
| Patel, SP | 1 |
| Duale, H | 1 |
| Lyttle, TS | 1 |
| O'Dell, CR | 1 |
| Kitzman, PH | 2 |
| Lapeyre, E | 1 |
| Kuks, JB | 1 |
| Meijler, WJ | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Arvio, M | 1 |
| Merikanto, J | 1 |
| Zafonte, R | 1 |
| Lombard, L | 1 |
| Elovic, E | 1 |
| Formica, A | 1 |
| Verger, K | 1 |
| Sol, JM | 1 |
| Morralla, C | 1 |
| Uhl, TL | 1 |
| Dwyer, MK | 1 |
| Priebe, MM | 2 |
| Sherwood, AM | 2 |
| Graves, DE | 1 |
| Mueller, M | 2 |
| Olson, WH | 3 |
| Mueller, ME | 1 |
| Gruenthal, M | 2 |
| Olson, WL | 2 |
| Cutter, NC | 1 |
| Scott, DD | 1 |
| Johnson, JC | 1 |
| Whiteneck, G | 1 |
| de Carvalho, M | 1 |
| Francisco, GE | 1 |
| Kothari, S | 1 |
| Huls, C | 1 |
| Schapiro, RT | 1 |
| Rösche, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for gabapentin and Clasp-Knife Spasticity
| Article | Year |
|---|---|
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
Spasticity: revisiting the role and the individual value of several pharmacological treatments.
Topics: Amines; Baclofen; Botulinum Toxins; Calcium Channel Blockers; Clonidine; Cyclohexanecarboxylic Acids | 2010 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
Antispasticity medications: uses and limitations of enteral therapy.
Topics: 4-Aminopyridine; Acetates; Adrenergic alpha-Agonists; Amines; Baclofen; Benzodiazepines; Cyclohexane | 2004 |
GABA agonists and gabapentin for spastic hypertonia.
Topics: Acetates; Amines; Animals; Anticonvulsants; Baclofen; Benzodiazepines; Cyclohexanecarboxylic Acids; | 2001 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
5 trials available for gabapentin and Clasp-Knife Spasticity
| Article | Year |
|---|---|
[Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial].
Topics: Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gamma-Ami | 2005 |
Effectiveness of gabapentin in controlling spasticity: a quantitative study.
Topics: Acetates; Adult; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1997 |
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acid | 1997 |
Gabapentin for the treatment of spasticity in patients with spinal cord injury.
Topics: Acetates; Administration, Oral; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarbo | 1997 |
Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cross-Over Studies; C | 2000 |
8 other studies available for gabapentin and Clasp-Knife Spasticity
| Article | Year |
|---|---|
Italian consensus on treatment of spasticity in multiple sclerosis.
Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections | 2020 |
Atypical cutaneous and musculoskeletal manifestation of SARS-CoV-2: 'COVID-19 toes' and spasticity in a 48-year-old woman.
Topics: Analgesics; Blister; COVID-19; Female; Foot Diseases; Gabapentin; Humans; Middle Aged; Muscle Spasti | 2021 |
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli | 2016 |
Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury.
Topics: Amines; Animals; Autonomic Dysreflexia; Cyclohexanecarboxylic Acids; Disease Models, Animal; Female; | 2011 |
[A relief from neural pain--gabapentin helped against hip ache in a girl with cerebral palsy].
Topics: Acetates; Adolescent; Amines; Analgesics; Arthralgia; Cerebral Palsy; Cyclohexanecarboxylic Acids; F | 2001 |
Gabapentin suppresses spasticity in the spinal cord-injured rat.
Topics: Amines; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Cross-Over Studies; Cycloh | 2007 |
Gabapentin for the treatment of spasticity in patients with amyotrophic lateral sclerosis.
Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Hu | 2001 |
Treatment of spasticity.
Topics: Acetates; Amines; Aminopyridines; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Clonidine; Cy | 2002 |